Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the best hot stocks to invest in. On October 6, Raymond James raised the firm’s price target on Monopar Therapeutics to $142 from $80, while keeping a Strong Buy rating on the shares. The firm thinks that the company’s shares can continue to work well into 2026.

Earlier in Q2 2025, the company’s net loss was $2.5 million (or $0.35 per share), compared to a net loss of $1.7 million (or $0.49 per share) for Q2 2024. Monopar Therapeutics reported that its cash, cash equivalents, and investments totaled $53.3 million, which will support operations through December 31, 2026.

Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy

This will allow the company to follow its anticipated timeline and execute tasks like filing an NDA for ALXN1840, concluding its Phase 1 imaging/dosimetry trial for MNPR-101-Zr, continuing its Phase 1a therapeutic trial for MNPR-101-Lu, and advancing its preclinical MNPR-101-Ac program into the clinic.

Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of cancer in the US.

While we acknowledge the potential of MNPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNPR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.